Economics Faculty Database
Economics
Arts & Sciences
Duke University
 HOME > Arts & Sciences > Economics > Faculty    Search Help Login pdf version printable version 

Publications of Henry G. Grabowski    :chronological  combined  bibtex listing:

Monographs

  1. "Patents and New Product Development in the Pharmaceuticals and Biotechnology Industries", edited by John Duca, Science and Cents: The Economics of Biotechnology (87-104), Federal Reserve Bank of Dallas [PDF]
  2. The Search for New Vaccines: The Effects of the Vaccines for Children Program (1997), American Enterprise Institute for Public Policy Research: Washington, D.C.
  3. Health Care Cost Containment and Pharmaceutical Innovation (1986), pp. 25-28, Proceedings of the Conferences on Health Care and the Elderly, Washington, D.C.
  4. with John Vernon, The Regulation of Pharmaceuticals: Balancing the Benefits and Risks (1983), American Enterprise Institute for Public Policy Research: Washington, D.C.
  5. The Effects of Product Quality Regulation on Innovation in the U.S. Pharmaceutical Industry (1979), Final Report for the National Science Foundation Grant PRA 75-19823 (National Technical Information Services, Washington, D.C.)
  6. with John Vernon, The Impact of Regulation on Industrial Innovation (1979), National Academy of Sciences: Washington, D.C.
  7. The Effects of Advertising on the Interindustry Distribution of Demand, Occasional Papers of National Bureau of Economic Research, Explorations in Economic Research, vol. 3 (Winter, 1976), pp. 21-75
  8. Drug Regulation and Innovation: Empirical Evidence and Policy Options (1976), American Enterprise Institute for Public Policy Research: Washington, D.C.

Journal Articles

  1. with Margaret Kyle, Richard Mortimer, Genia Long and Noam Kirson, Evolving Brand-Name and Generic Competition May Warrant a Revision of the Hatch-Waxman Act, Health Affairs, vol. 30 no. 11 (November, 2011), pp. 2157-2166 [PDF]
  2. The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection, International Journal of the Economics of Business, vol. 18 no. 2 (July, 2011), pp. 161-176 [PDF]
  3. with Genia Long and Richard Mortimer, Data Exclusivity for Biologics, Nature Reviews Drug Discovery, vol. 10 no. 1 (January, 2011), pp. 15-16 (PDF also includes the on-line supplementary material published in connection with this article..) [PDF]
  4. with Genia long and Richard Mortimer, Implementation of the Biosimilar Pathway: Economic and Policy Issues, Seton Hall Law Review, vol. 41 no. 2 (2011), pp. 511-557 [PDF]
  5. Follow-on biologics: data exclusivity and the balance between innovation and competition, Nature Reviews Drug Discovery, vol. 7 no. 6 (June, 2008), pp. 479-488 [PDF]
  6. with Y Richard Wang, Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act, Journal of Law and Economics (May, 2008), pp. 377-406 [PDF]
  7. with Jeffrey L. Moe, Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention, Cancer Prevention Research (2008) [PDF]
  8. with JA DiMasi, Should the Patent System for New Medicines Be Abolished, Clinical Pharmacology & Therapeutics, vol. 82 no. 5 (November, 2007), pp. 488-491 [PDF]
  9. with Jeffrey L. Moe, Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention, Duke Department of Economics Working Papers (November, 2007) [PDF]
  10. with David Ridley, and Kevin Schulman, Entry and Competition in Generic Biologics, Managerial and Decision Economics, vol. 28 (2007), pp. 439-451 [PDF]
  11. with Jennifer Li, Eric Eisenstein, Elizabeth Reid, Barry Mangum, Kevin Schulman, John Goldsmith, M Dianne Murphy, Robert Califf, and Daniel Benjamin, Jr., Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program, Journal of the American Medical Association, vol. 297 no. 5 (2007), pp. 480-488 [PDF]
  12. with Joseph DiMasi, The Economics of New Oncology Drug Development, Journal of Clinical Oncology, vol. 25 no. 2 (2007), pp. 209-216 [PDF]
  13. with Joseph DiMasi, The Cost of Pharmaceutical R&D: Is Biotech Different?, Managerial and Decision Economics, vol. 28 (2007), pp. 469-479 [PDF]
  14. with Margaret Kyle, Generic Competition and Market Exclusivity Periods in Pharmaceuticals, Managerial and Decision Economics, vol. 28 (2007), pp. 491-502 [PDF]
  15. with Omar Gokcekus, Mike Adams, and Edward Tower, How Did the 2003 Prescription Drug Re-Importation Bill Pass The House?, Economics & Politics, vol. 18 no. 1 (March, 2006), pp. 27-45 [PDF]
  16. with Atanu Saha, Howard Birnbaum, Paul Greenberg, and Oded Bizan, Generic Competition in the U.S. Pharmaceutical Industry, International Journal of the Economics of Business (February, 2006) (Vol. 13, Issue 1, pp. 15-38.) [PDF]
  17. with Iain Cockburn, Genia Long, The Market for Follow-On Biologics: How Will It Evolve?, Health Affairs, vol. 25 no. 5 (2006), pp. 1291-1301 [PDF]
  18. with Y. Richard Wang, The Quantity and Quality of Worldwide New Drug Introductions 1992 - 2003, Health Affairs, vol. 25 no. 2 (2006), pp. 452-460 [PDF]
  19. with David Ridley, Judith Kramer, Hugh Tilson, and Kevin Schulman, Spending on Post-approval Drug Safety, Health Affairs, vol. 25 no. 2 (2006), pp. 429-436 [PDF]
  20. with David Ridley and Jeffrey Moe, Developing Drugs for Developing Countries, Health Affairs, vol. 25 no. 2 (2006), pp. 313-324 [PDF]
  21. H.G. Grabowski, Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act, in Cambridge University Press Conference Volume, edited by Jerome Reichman (2005), pp. 457-480 [PDF] [abs]
  22. with Joseph DiMasi and Ronald Hansen, Extraordinary Claims Require Extraordinary Evidence, Journal of Health Economics, vol. 24 no. 5 (2005), pp. 1034 - 1044 [PDF]
  23. with Joseph DiMasi, Ronald Hansen, Setting the Record Straight on Setting the Record Straight: Response to Light and Warburton's Rejoiner, Journal of Health Economics, vol. 24 no. 5 (2005), pp. 1049 [PDF]
  24. Encouraging the Development of New Vaccines, Health Affairs, vol. 24 no. 3 (2005), pp. 697-704 [PDF]
  25. with Joseph DiMasi, and John Vernon, R&D Costs and Returns by Therapeutic Category, Drug Information Journal (2004) [PDF]
  26. Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures, PharmacoEconomics, vol. 22, suppl. 2 (2004), pp. 15-24 [PDF] [abs]
  27. The Ripple Effects of a Restrictive Medicaid Formulary (editorial), American Journal of Managed Care, vol. 9 no. 10 (October, 2003), pp. 648-649 [PDF]
  28. Patents and New Product Development in the Pharmaceutical and Biotechnology Industry, The Georgetown Public Policy Review, vol. 8 no. 2 (Spring, 2003), pp. 7-23 [PDF]
  29. with Joseph DiMasi and Ronald Hansen, The Price of Innovation: New Estimates of Drug Development Costs, Journal of Health Economics, vol. 22 (2003), pp. 141-185 [PDF]
  30. Patents, Innovation and Access to New Pharmaceuticals, Journal of International Economic Law (February, 2002), pp. 849-860 (Also presented at the American Association for the Advancement of Science, Annual Meetings, Boston.) [PDF]
  31. with John Vernon and Joe DiMasi, Returns on R&D for 1990s New Drug Introductions, PharmacoEconomics, vol. 20 no. Supplement 3 (2002) [PDF]
  32. with John Vernon, The Determinants of Pharmaceutical Research and Development Expenditures, Journal of Evolutionary Economics, vol. 10 (2000), pp. 201-215 [PDF]
  33. with John Vernon, Effective Patent Life in Pharmaceuticals, International Journal of Technology Management, vol. 19 no. 1/2 (2000), pp. 98-120 [PDF]
  34. with John Vernon, The Distribution of Sales Revenues from Pharmaceutical Innovation, Pharmacoeconomics, vol. 18 no. suppl. 1 (2000), pp. 21-32 [PDF]
  35. The Role of Cost-Effectiveness Analysis in Managed Care Decisions, Pharmacoeconomics, vol. 14,suppl. 1 (1998), pp. 15-24 [PDF]
  36. with Frank Sloan, "The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective", Social Science & Medicine, vol. 45 no. 4 (August, 1997) (Edited Symposium Volume.)
  37. with Daniel C. Mullins, Pharmacy, Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions, Social Science & Medicine, vol. 45 no. 4 (August, 1997), pp. 535-544 [PDF]
  38. The Effect of Pharmacoeconomics on Company Research and Development Decisions, PharmacoEconomics, vol. 11 no. 5 (May, 1997), pp. 389-397
  39. Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade, PharmacoEconomics, vol. 10,Suppl. 2 (1996), pp. 110-123 [PDF]
  40. with Joseph DiMasi, Ronald Hansen and Louis Lasagna, Research and Development Costs for New Drugs by Therapeutic Category: A Study of the U.S. Pharmaceutical Industry, PharmacoEconomics, vol. 7 no. 2 (1995), pp. 152-169
  41. with Joseph A. DiMasi and John Vernon, R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry, International Journal of the Economics of Business, vol. 2 no. 2 (1995), pp. 201-219 (Special volume honoring Merton J. Peck of Yale University.) [PDF]
  42. Health Reform and Pharmaceutical Innovation, Seton Hall Law Review, vol. 24 no. 3 (1994), pp. 1221-1259 [PDF]
  43. with John Vernon, Innovation and Structural Change in Pharmaceuticals and Biotechnology, Industrial and Corporate Change, vol. 3 no. 2 (1994), pp. 435-449 [PDF]
  44. with John Vernon, Returns to R&D on New Drug Introductions in the 1980s, Journal of Health Economics, vol. 13 (1994), pp. 383-406 [PDF]
  45. with John M. Vernon, Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act, Journal of Law and Economics, vol. 35 no. 2 (October, 1992), pp. 331-350 [PDF]
  46. The Costs and Returns to Pharmaceutical Research and Development, Revista Internazionale di Scienze sociali (International Social Studies Review) (September, 1992), pp. 347-358 [PDF]
  47. with The Costs and Returns to Pharmaceutical Research and Development, Rivista internazionale di scienze sociali, vol. 3 (September, 1992), pp. 347-357 [PDF]
  48. with Stuart O. Schweitzer and S. Renee Shiota, The Effect of Medicaid Formularies on the Availability of New Drugs, PharmoEconomics, vol. 1(Suppl. 1) (1992), pp. 32-40
  49. with Joseph DiMasi, Ronald Hansen and Louis Lasagna, The Cost of Innovation in the Pharmaceutical Industry, Johnal of Health Economics, vol. 10 (1991), pp. 107-142 [PDF]
  50. with John Vernon, A New Look at the Returns and Risks to Pharmaceutical R & D, Management Science, vol. 36 no. 7 (July, 1990), pp. 804-821 [PDF]
  51. with W. Kip Viscusi and William N. Evans, Price and Availability Tradeoffs of Automobile Insurance Regulation, Journal of Risk and Insurance, vol. LVI no. 2 (June, 1989), pp. 275-299 [PDF]
  52. An Analysis of U.S. International Competitiveness in Pharmaceuticals, Managerial and Decision Economics, Special Issue (1989), pp. 27-33 [PDF]
  53. Medicaid Patients' Access to New Drugs, Health Affairs (Winter, 1988), pp. 102-114 [PDF]
  54. with John Vernon, Pioneers, Imitators, and Genetics--A Simulation Model of Schumpeterian Competition, The Quarterly Journal of Economics (August, 1987), pp. 491-525
  55. The Health/Economic Benefits of Drug Therapy: Efficacy, Low Risk, Cost Effectiveness, Patient Information and Emancipation, Swiss Pharma, vol. 9 no. 3a (1987), pp. 29-31
  56. with John Vernon, Longer Patents for Lower Imitation Barriers: The 1984 Drug Act, The American Economic Review, vol. 76 no. 2 (May, 1986), pp. 195-198 [PDF]
  57. with Michael Gort and Robert McGuckin, Organizational Capital and the Choice between Specialization and Diversification, Managerial and Decision Economics, vol. 6 no. 1 (March, 1985), pp. 2-10
  58. H.G. Grabowski, The Impact of Patent and Regulatory Policies on Drug Innovation, Medical Marketing & Media, vol. 18 no. 10 (October, 1983), pp. 42-63
  59. H.G. Grabowski with Richard J. Arnould, Automobile Safety Regulation: A Review of the Evidence, edited by Richard O. Zerbe, Research in Law and Economics, vol. 5 (1983), pp. 233-267
  60. Public Policy and Pharmaceutical Innovation, Health Care Financing Review, vol. 4 no. 1 (September, 1982), pp. 75-87
  61. with John Vernon, A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development, Managerial and Decision Economics, vol. 3 no. 1 (March, 1982), pp. 36-40 [PDF]
  62. Public Policy and Innovation: The Case of Pharmaceuticals, Technovation, vol. 1 (1982), pp. 157-189
  63. with Richard J. Arnould, Auto Safety Regulation: An Analysis of Market Failure, The Bell Journal of Economics, vol. 12 no. 1 (Spring, 1981), pp. 27-48
  64. The Impact of Regulation on Innovation, Food Drug Cosmetic Law Journal, vol. 34 no. 10 (October, 1979), pp. 555-560
  65. with John Vernon, Substitution Laws and Innovation in the Pharmaceutical Industry, Law and Contemporary Problems (Winter/Spring Issue 1979), pp. 43-66 [PDF]
  66. with Dennis Mueller, Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates, Bell Journal of Economics, vol. 9 no. 2 (Fall, 1978), pp. 328-343
  67. The Effects of Advertising on IntraIndustry Shifts on Demand, Occasional Papers of the National Bureau of Economic Research, Explorations in Economic Research, vol. 4 no. 5 (Fall, 1978), pp. 675-701
  68. with John M. Vernon, Consumer Product Safety Regulation, American Economic Review, vol. 68 (May, 1978), pp. 284-289
  69. with Vernon, John and Thomas, Lacy Glen, Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry, Journal of Law and Economics, vol. 21 no. 1 (April, 1978), pp. 133-163 [PDF]
  70. with John M. Vernon and Lacy Glenn Thomas, Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry, Journal of Law and Economics, vol. 21 no. 1 (April, 1978), pp. 133-163
  71. with John Vernon, Consumer Protection Regulation in Ethical Drugs, American Economic Review, vol. 67 no. 1 (February, 1977), pp. 359-364 [PDF]
  72. with C. Dennis Mueller, Life Cycle Effects on Corporate Returns on Retentions, Review of Economics and Statistics, vol. 57 (November, 1975), pp. 400-409
  73. with Nevins D. Baxter, Rivalry in Research and Development: An Empirical Study, Journal of Industrial Economics, vol. 21 no. 2 (July, 1973), pp. 209-235
  74. with A. Corazzani and D. Dugan, Determinants and Distributional Aspects of Enrollment in U.S. Higher Education, Journal of Human Resources, vol. 7 no. 1 (Winter, 1972), pp. 39-59 [PDF]
  75. with Dennis Mueller, Managerial and Stockholder Welfare Models of Firm Expenditures, Review of Economics and Statistics, vol. 54 (February, 1972), pp. 9-24 [PDF]
  76. with Dennis Mueller, Imitative Advertising in the Cigarette Industry, The Journal of American and Foreign Antitrust and Trade Regulations, vol. 16 no. 2 (Summer, 1971), pp. 257-292
  77. with Dennis Mueller, Non-Price Competition in the Cigarette Industry: A Coment, Antitrust Bulletin, vol. 40 (Winter, 1970), pp. 257-292
  78. with Dennis Mueller, Industrial Organization: The Role and Contribution of Econometrics, American Economic Review, vol. 60 no. 2 (May, 1970), pp. 100-104 [PDF]
  79. Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making, Quarterly Journal of Econoics, vol. 84 (May, 1970), pp. 217-235 [PDF]
  80. with The Determinents of Research and Development: A study of the chemical, drug, and petrolium industries, Journal of Political Economy, vol. 76 no. 2 (1968), pp. 292-306 (reprinted in K.S. Palda, ed., Readings in Managerial Economics, (Prentice-Hall), 1973; also reprinted in S. Yarney, ed., Economics of Industrial Structure: Selected Readings, (Penguine Modern Economics Series), 1973.) [PDF]

Chapters in Books

  1. with Joseph DiMasi, R&D Costs and Returns, in The Handbook of Pharmaceuticals, edited by OPatricia Danzon and Sean Nichols (2011), Oxford University Press (Forthcoming.)
  2. with David B. Ridley & Jeffrey L. Moe, Encouraging innovative treatment of neglected diseases through priority review vouchers, in Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, edited by Karen Eggleston (2009), pp. 347-365, The Walter H, Shorenstein Asia-Pacific Research Center, Stanford University [PDF]
  3. with Margaret Kyle, Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity, in The Economics of Corporate Governance and Mergers, edited by Klaus Gugler and B. Burcin Yurtoglu (2008), pp. 262-287, Edward Elgar Publishing, Northampton, MA, ISBN 978 1 84720 719 [PDF]
  4. H.G. Grabowski, Competition Between Generic and Branded Drugs, in Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, edited by F. A. Sloan and C. T. Hsieh (2007), pp. 153-173, Cambridge University Press [PDF]
  5. Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act, in International Public Goods, and Transfer of Technology Under a Globalized Intellectual Property Regime, edited by Keith E. Maskus and Jerome H. Reichman (2005), pp. 457-480, Cambridge University Press (Published by Cambridge University Press (Conference volume).) [Pdf] [abs]
  6. Patents and the Development of New Pharmaceuticals in Pharmaceuticals and Biotechnology Industry, in Science and Cents: Exploring the Economics of Biotechnology, edited by Duca John V and Yucel, Mine K (2003), pp. 87-104, Federal Reserve Bank of Dallas (Proceedings of the 2002 Conference on Exploring the Economics of Biotechnology.) [PDF]
  7. with John Vernon, Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure, in Consolidation and Competition in the Pharmaceutical Industry, edited by Hannah E. Kettler (2001), pp. 62-79, Office of Health Economics, London [PDF]
  8. Public Policy and Innovation in Pharmaceuticals and Biotechnology, in Business and Economics for the 21st Century, Volume 1, edited by Demetri Kantarelis (1997), pp. 343-349, Business and Economic Society International, Worcester, Mass.
  9. with Ronald W. Hansen, Economic Scales and Tests, in Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition, edited by B. Spilker (1996), pp. 79-84, Lippincott-Raven Press: Philadelphia
  10. with John Vernon, Returns to Pharmaceutical R&D: Prospects Under Health Care Reform, in Competitive Strategies in the Pharmaceutical Industry, edited by Robert Helms (1996), pp. 194-207, AEI Press: Washington, D.C.
  11. with Gary Zarkin, Josephine Mauskopf, Heather A. Bannerman, and Richard H. Weisler, Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol" Chapter 16, in Psychopharmacology: The Fourth Generation of Progress, edited by Floyd E. Bloom and David J. Kupfer (1995), pp. 1897-1905, Raven Press, Ltd.: NY [PDF]
  12. Price and Profit Control, New Competitive Dynamics and the Economics of Innovation in the Pharmaceutical Industry, in Industrial Policy and the Pharmaceutical Industry, edited by Adrian Towse (1995), pp. 77-91, Office of Health Economics: London [PDF]
  13. The Changing Economics of Pharmaceutical Research and Development, in The Changing Economics of Medical Technology, edited by Annetine C. Gelijns and Ethan A. Halm (1991), pp. 35-52, National Academy Press: Washington, D.C. [PDF]
  14. Product Liability in the Pharmaceuticals: Comments on Chapters Eight and Nine, in The Liability Maze: The Impact of Liability Law on Safety and Innovation, edited by Peter W. Huber and Robert E. Litan (1991), pp. 360-366, Brookings Institution: Washington, D.C. [PDF]
  15. with Ronald W. Hansen, Economic Scales and Tests, in Quality of Life Assessments in Clinical Trials, edited by B. Spilker (1990), pp. 61-69, Raven Press, Ltd.: New York
  16. Innovation and International Competitiveness in Pharmaceuticals, in Evolving Technology and Market Structure: Studies in Schumpeterian Economics, edited by Arnold Heertje and Mark Perlman (1990), pp. 167-185, University of Michigan Press [PDF]
  17. with Lawrence De Brock, Economic Aspects of Vaccine Innovation and Manufacturing Chapter, in Vaccine Supply and Innovation (1985), pp. 45-64, National Academy Press: Washington, D.C.
  18. with John Vernon, A Computer Simulation Model of Pharmaceutical Innovation, in Pharmaceutical Economics, edited by Bjorn Lindgren (1984), pp. 159-175, Swedish Institute for Health Economics and Liber Forlag: Lund, Sweden [PDF]
  19. with John M. Vernon, The Pharmaceutical Industry, in Government and Technical Progress - A Cross-Industry Analysis, edited by Richard R. Nelson (1982), pp. 283-360, Pergamon Press: New York [PDF]
  20. with Jean P. Gagnon, An Evaluation of the Maximum Allowable Cost Program, in The Effectiveness of Medicines in Containing Health Care Costs (1982), pp. 81-113, Proceedings of a Symposium of the National Pharmaceutical Council, Washington, D.C.
  21. with John Vernon, The Determinants of R&D Expenditures, in Drugs and Health, edited by Robert B. Helms (1981), pp. 3-20, American Enterprise Institute for Public Policy Research: Washington, D.C.
  22. Regulation and Industrial Innovation, in Industrial Innovation and Public Policy Options: Background Papers for a Colloquium (1981), pp. 65-81, National Academy Press: Washington, D.C.
  23. Regulation and the International Diffusion of Pharmaceuticals, in The International Supply of Medicines, edited by Robert B. Helms (1980), pp. 5-36, American Enterprise Institute for Public Policy Research: Washington, D.C.
  24. with John M. Vernon, New Studies on Market Definition, Concentration, Theory of Supply, Entry and Promotion, in Issues in Pharmaceutical Economics, edited by Robert I. Chien (1979), pp. 29-52, Lexington Books: Lexington, Mass.
  25. Regulation of the United States Pharmaceutical Industry: Current Problems and Policy Developments, in Medicines for the Year 2000, edited by George Teeling-Smith (1979), pp. 57-74, Office of Health Economics: London, England
  26. with John Vernon, Structural Effects of Regulation on Innovation in the Ethical Drug Industry" (Chapter 10, in Essays on Industrial Organization in Honor of Joe S. Bain, edited by Robert T. Masson and P. David Qualls (1976), pp. 181-205, Ballinger Publishing Company: Cambridge [PDF]
  27. with John Vernon and Lacy Glenn Thomas, The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis, in Impact of Public Policy on Drug Innovation and Pricing, edited by Emery A. Link and Samuel Mitchell (1976), pp. 47-93, American University: Washington, D.C. [PDF]
  28. Advertising and Resource Allocation: A Critique, in Advertising and the Public Interest, edited by Salvatore F. Davita (1974), American Marketing Association
  29. with Oscar Morgenstern and R.W. Shepherd, A Graph-Oriented Model for Research Management, in Research Program Effectiveness, edited by M.C. Yovits, D.M. Gilford, E. Staveley and H.D. Lerner (1966), pp. 187-216, Gordon and Breach: New York [PD]

Other

  1. Returns to Pharmaceutical R&D in the 1990s (July, 2001) (Tufts University Conference, Center for the Study of Drug Development, Talloires France.)
  2. Patent Policy Issues in Pharmaceuticals (March, 2001) (Robert Wood Johnson Foundation Colloquium on the Pharmaceutical Industry, Washington, D.C..)
  3. New Research on the Returns to Pharmaceutical R & D (October, 2000) (American Enterprise Institute, Washington, D.C..)
  4. The Distribution of Sales Revenues from Pharmaceutical Innovation (June, 2000) (Schumpeterian Society Meetings, Manchester, England.)
  5. "Effective Patent Life in Pharmaceuticals" (June, 1999) (U.S. House of Representatives Colloquium for House Staff Members.)
  6. Health Reform and Pharmaceutical Innovation (1994), American Enterprise Institute for Public Policy Research: Washington, D.C. (American Enterprise Institute for Public Policy Research, Washington, D.C..)
  7. Testimony - Health Care Reform (1994) [PDF] [author's comments]
  8. Pharmaceuticals and Health Care Costs (October, 1993), Proceedings of the First International Health Care Forum, Health Care Policy and the Pharmaceutical Industry, Gotemba, Japan (International Health Care Forum, "Health Care Policy and the Pharmaceutical Industry," Gotemba, Japan.) [PDF]
  9. Pharmaceutical Research and Development: Return and Risk (1991), Centre for Medicines Research, Surrey, England (Sixth Annual Centre for Medicines Research Lecture, Centre for Medicine Research, Surrey, England.)
  10. Impact of Patent and Regulatory Policies on Drug Innovation, in Proceedings of the Second Annual Shearson Lehman Hutton Conference on Legal and Regulatory Issues Affecting Biotechnology and Health Care (October, 1988), pp. 5-16
  11. Studies on Drug Substitution, Patent Policy and Innovation in the Pharmaceutical Industry (1985) (Final report to the National Science Foundation available from the National Technical Information Services, Number PB-85-109700, Washington, D.C..)
  12. A Computer Simulation Model of Pharmaceutical Innovation, in Pharmaceutical Economics with John Vernon, edited by B. Lindgren (1982), Liber Forlag (Presented at the Arne Ryde Symposium Helsingborg, Sweden.) [PDF]
  13. Testimony - Patent Term Restoration Act of 1981 (1981) [PDF] [author's comments]
Duke University * Arts & Sciences * Economics * Faculty * Research * Staff * Masters * PhD * Reload * Login